PBGH Announcements
For Media Inquiries:
EmployersRx: Congress Must Reduce Drug Costs for Everyone
Congressional leaders are currently drafting legislation that would allow the federal government to negotiate the price of high-cost drugs and those newly entering the market.
Final Approval Granted for the Sutter Health Settlement
The settlement agreement achieved in the Sutter Health case, along with the injunctive relief, will have a significant and beneficial economic impact.
PBGH Statement on President Biden’s Remarks on Lowering Drug Costs
Addressing health care costs, and in particular the cost of prescription drugs, is an economic issue. Earnings siphoned off by health care costs limit job creation and wage growth, divert investment and cripple competitiveness and innovation.
PBGH Statement in Response to CMS Raising Penalties for Hospitals Failing to Make Prices Public
We are very pleased that the Biden administration is signaling its intention to aggressively implement the previous administration’s hospital price transparency rule.
Purchaser Business Group on Health Appoints Four New Members to Its Board of Directors
The Purchaser Business Group on Health (PBGH) has announced the addition of four new board members.
PBGH statement on President Biden’s Executive Order on Promoting Competition in the American Economy
We are exceptionally pleased by the messages in President Biden’s Executive Order on Promoting Competition in the American Economy.
National and Regional Employer Groups Partner in Colorado to Jointly Contract with High-Quality Health Care Providers, Centers of Excellence
PBGH and TCPA will contract directly with centers of excellence for select procedures; physician practices and physician-governed organizations will also be engaged to manage chronic disease, a primary driver of health care costs for employers, more effectively.
PBGH Thanks President Biden for Leadership on Drug Costs
President Biden reaffirm his commitment to support legislation to meaningfully bring down the price of prescription drugs in the United States in his speech to a Joint Session of Congress on April 28.
Vast Majority of Large Employers Surveyed Say Broader Government Role Will Be Necessary to Control Health Costs and Provide Coverage
Most business leaders favor increased anti-trust enforcement, prohibitions on anti-competitive practices, capping drug and hospital prices in non-competitive markets; a public option and lower medicare eligibility age seen as viable options.
EmployersRx for Greater Transparency, Competition and Value in Drug Pricing
The EmployersRx agenda aligns with the Biden administration’s objectives of reducing care costs and strengthening access while addressing the widespread health system vulnerabilities exposed by the pandemic.
